TOXICITY OF THE ANTITUMORAL DRUG DATELLIPTIUM IN HEPATIC CELLS - USE OF MODELS INVITRO FOR THE PREDICTION OF TOXICITY INVIVO

被引:3
作者
DONATO, MT [1 ]
GOETHALS, F [1 ]
GOMEZLECHON, MJ [1 ]
DEBOYSER, D [1 ]
DECOSTER, I [1 ]
ROBERFROID, M [1 ]
CASTELL, JV [1 ]
机构
[1] UNIV CATHOLIQUE LOUVAIN, BIOCHIM TOXICOL & CANCEROL LAB, B-1200 BRUSSELS, BELGIUM
关键词
D O I
10.1016/0887-2333(92)90019-N
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Datelliptium is a DNA-intercalating agent derived from ellipticine. The drug has potent antitumoral activity in vitro and in vivo. The first clinical use of the drug revealed unexpected hepatotoxic effects in humans that had not been observed in animals. Using different hepatic models in vitro (rat hepatocytes in suspension and in culture, cultured human hepatocytes and rat and human hepatoma cell lines), the possibility of prediction in vitro of the hepatic toxicity of a drug has been investigated. Cytotoxic effects were evaluated by measuring the leakage of intracellular lactate dehydrogenase and the ability of cells to reduce MTT after exposure to concentrations of datelliptium ranging from 0.1 to 1000 muM. According to these endpoint parameters, the concentrations of the drug that produced 50% of maximal inhibitory effect (IC50) were in the range 100 to 195 muM in rat hepatocyte suspension and hepatocyte cultures after 2 hr of treatment, 7-9 muM in cultured rat and human hepatocytes after 23 hr of treatment, and about 200-320 muM in HepG2 and FaO cells after 23 hr of treatment. Metabolic parameters were generally more sensitive than cytotoxic endpoints for detecting toxic effects of datelliptium on hepatocytes in the two experimental models used. Metabolic effects on rat hepatocyte suspension and culture were evaluated respectively after 2 and 23 hr of exposure to the drug. Triglyceride secretion was the most sensitive parameter and the IC10 values (concentration causing 10% of maximal inhibitory effect) were 0.03 and 0.9 muM in hepatocyte suspension and culture, respectively. Glycogen, albumin and cellular protein synthesis were similarly altered in both cellular systems and the IC10 values were in the range 0.5-3.5 muM. Ureogenesis and gluconeogenesis were relatively insensitive parameters in cell suspensions (IC10 values 16.4 and 10.3 muM, respectively) compared with those in hepatocyte culture (IC10 values 3.6 and 3.1 muM, respectively). The concentrations of datelliptium reported in blood, and particularly in liver, are higher than the concentrations that produce impairment of cell metabolism in vitro. This may be an indicator of the toxicological risk of datelliptium and anticipates the hepatotoxicity observed in vivo.
引用
收藏
页码:295 / 302
页数:8
相关论文
共 25 条
[1]   AUTOXIDATION OF THE ANTI-TUMOR DRUG 9-HYDROXYELLIPTICINE AND ITS DERIVATIVES [J].
AUCLAIR, C ;
HYLAND, K ;
PAOLETTI, C .
JOURNAL OF MEDICINAL CHEMISTRY, 1983, 26 (10) :1438-1444
[2]  
AUCLAIR C, 1987, CANCER RES, V47, P6254
[3]   COMPARISONS OF 2-INVITRO CYTO-TOXICITY ASSAYS - THE NEUTRAL RED (NR) AND TETRAZOLIUM MTT TESTS [J].
BORENFREUND, E ;
BABICH, H ;
MARTINALGUACIL, N .
TOXICOLOGY IN VITRO, 1988, 2 (01) :1-6
[4]   A STUDY OF THE RELATIVE HEPATOTOXICITY INVITRO OF THE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS IBUPROFEN, FLURBIPROFEN AND BUTIBUFEN [J].
CASTELL, JV ;
LARRAURI, A ;
GOMEZLECHON, MJ .
XENOBIOTICA, 1988, 18 (06) :737-745
[5]   EFFECTS OF BENORYLATE AND IMPACINA ON THE METABOLISM OF CULTURED-HEPATOCYTES [J].
CASTELL, JVM ;
MONTOYA, A ;
LARRAURI, A ;
LOPEZ, P ;
GOMEZL, J .
XENOBIOTICA, 1985, 15 (8-9) :743-749
[6]   INVESTIGATION INTO THE MECHANISM OF TETRACYCLINE-INDUCED STEATOSIS - STUDY IN ISOLATED HEPATOCYTES [J].
DEBOYSER, D ;
GOETHALS, F ;
KRACK, G ;
ROBERFROID, M .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1989, 97 (03) :473-479
[7]  
FELLOUS R, 1989, THESIS U RENE DESCAR
[8]   CRITICAL BIOCHEMICAL FUNCTIONS OF ISOLATED HEPATOCYTES AS SENSITIVE INDICATORS OF CHEMICAL TOXICITY [J].
GOETHALS, F ;
KRACK, G ;
DEBOYSER, D ;
VOSSEN, P ;
ROBERFROID, M .
FUNDAMENTAL AND APPLIED TOXICOLOGY, 1984, 4 (03) :441-450
[9]  
GOMEZL MJ, 1984, IN VITRO CELL DEV B, V20, P826
[10]  
GOMEZLECHON MJ, 1990, IN VITRO CELL DEV B, V26, P67